Keep you informed

Welcome to the Galenicum Axium news section. In this site, we will inform you about the latest updates of the company together with the most relevant product updates.

In Galenicum Axium, we are committed to our customers and partners, and we want to keep you informed with all the latest achievements of the company and the projects we are working on.

New York - DCAT WEEK

Galenicum visits New York during DCAT Week

After Galenicum's attendance at the CPhI in Milano the last month of November, it is time for new pharma events. We are visiting DCAT Week in New York City from 21st until 24th of March, 2022.

For one week, Galenicum will be in New York in order to meet partners, and to potentially find new ones. Are you willing to meet any of our representatives in the event? Do not hesitate to contact us at hello@galenicum.com

Read more

Midostaurin NCE-1

Galenicum partner files Midostaurin in the US

In 2021, Galenicum Axium accomplished an important milestone with the submission of Midostaurin soft gel capsules 25mg Dossier to the US FDA on the NCE-1 date.

Midostaurin is an oral prescription medicine used to treat adults with a certain type of Acute Myeloid Leukemia (AML), and whose innovator is RYDAPT® from Novartis.

Living up to our mission of improving the quality and affordability of pharmaceutical products worldwide, Midostaurin has been a great addition to our broad portfolio of products. Are you interested? Please, contact us or continue reading. 

Read More

Visit us at CPhI Milano 2021

CPhI 2021 Milano

Galenicum will be exhibiting at the CPhI Worldwide 2021 in Milan from November 9th to 11th.

We have already booked slots with most of our partners. However, if you still do not have an appointment but would like to discuss potential business opportunities, come and meet us at Hall 1 (FDF), Stand F31. We are very excited to meet you in person after such a long time!

Read more

Thanks for reaching out. We will get back to you as soon as possible.

RESTRICTED ACCESS

The information contained in this section is aimed at the healthcare professional of the Pharmaceutical Industry, therefore, specialized training is required for its correct interpretation.

The products mentioned may have a different authorized data sheet in each country.

If you click the "accept" button, you are expressing your willingness to access the information explicitly intended for healthcare professionals.

DABIGAMAX

DEVELOPMENT OF THE FIRST GENERIC PHARMACEUTICAL SPECIALTY WITH DABIGATRAN. Decision EMC/2755/2017, dated November 20, (DOGC núm. 7508 of 30/11/2017) regarding the call for NUCLEUS OF INDUSTRIAL RESEARCH AND EXPERIMENTAL DEVELOPMENT (file number RD17-1-0006). This project has received funding from the European Union through the European Regional Development Fund (ERDF). With the collaboration from ACCIÓ.